Deciphering β-lactamase-independent p-lactam resistance evolution trajectories in Pseudomonas aeruginosa

被引:35
|
作者
Cabot, Gabriel
Florit-Mendoza, Llorenc
Sanchez-Diener, Irina
Zamorano, Laura
Oliver, Antonio [1 ]
机构
[1] Hosp Univ Son Espases, Serv Microbiol, Inst Invest Sanitaria Illes Balea IdISBa, Palma De Mallorca, Spain
关键词
CYSTIC-FIBROSIS; ANTIMICROBIAL RESISTANCE; CEFTOLOZANE-TAZOBACTAM; GENETIC-DETERMINANTS; STRAINS; SUSCEPTIBILITY; INFECTIONS; ADAPTATION; SEQUENCE; DELETION;
D O I
10.1093/jac/dky364
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: While resistance related to the expression of beta-Eactamases, such as AmpC from Pseudomonas aeruginosa, has been deeply studied, this work addresses the gap in the knowledge of other potential bacterial strategies to overcome the activity of beta-lactams when beta-lactamases are not expressed. Methods: We analysed 13-lactam resistance evolution trajectories in a WT strain and in isogenic mutants either lacking AmpC (AmpC mutant) or unable to express it (AmpG mutant), exposed to increasing concentrations of ceftazidime for 7 days in quintuplicate experiments, Characterization of evolved lineages included susceptibility profiles, whole-genome sequences, resistance mechanisms, fitness (competitive growth assays) and virulence (Caenorhabditis elegans model). Results: Development of resistance was faster for the WT strain but, after 7 days, all strains reached clinical ceftazidime resistance levels, The main resistance mechanism in the WT strain was ampC overexpression, due to mutations in clacB and ampD or mpl, In contrast, ampC overexpression did not evolve in any of the AmpG lineages. Moreover, sequencing of the Delta AmpC and Delta AmpG evolved lineages revealed alternative resistance mutations (not seen in WT lineages) that included, in all cases, large (50-600 kb) deletions of specific chromosomal regions together with mutations leading to p-lactam target [ftsI (PBP3)] modification and/or the overexpression or structural modification of the efflux pump MexAB-OprM. Finally, evolved lineages from the AmpC and, especially, AmpG mutants showed a reduced fitness and virulence. Conclusions: In addition to providing new insights intop-lactam resistance mechanisms and evolution, our findings should be helpful for guiding future strategies to combat P. aeruginosa nfections.
引用
收藏
页码:3322 / 3331
页数:10
相关论文
共 50 条
  • [1] Potentiation of p-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates
    Idowu, Temilolu
    Ammeter, Derek
    Arthur, Gilbert
    Zhanel, George G.
    Schweizer, Frank
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2640 - 2648
  • [2] Studies on the mechanisms of P-lactam resistance in Bordetella bronchiseptica
    Kadlec, Kristina
    Wiegand, Irith
    Kehrenberg, Corinna
    Schwarz, Stefan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (03) : 396 - 402
  • [3] Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
    Barnes, Melissa D.
    Taracila, Magdalena A.
    Rutter, Joseph D.
    Bethel, Christopher R.
    Galdadas, Ioannis
    Hujer, Andrea M.
    Caselli, Emilia
    Prati, Fabio
    Dekker, John P.
    Papp-Wallace, Krisztina M.
    Haider, Shozeb
    Bonomo, Robert A.
    MBIO, 2018, 9 (06):
  • [4] RESISTANCE OF PSEUDOMONAS-AERUGINOSA TO IMIPENEM IS INDEPENDENT OF BETA-LACTAMASE PRODUCTION
    BUSCHER, KH
    CULLMANN, W
    OPFERKUCH, W
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (05) : 700 - 701
  • [5] ROLES OF PORIN AND BETA-LACTAMASE IN BETA-LACTAM RESISTANCE OF PSEUDOMONAS-AERUGINOSA
    HANCOCK, REW
    WOODRUFF, WA
    REVIEWS OF INFECTIOUS DISEASES, 1988, 10 (04): : 770 - 775
  • [6] Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
    Wolter, Daniel J.
    Lister, Philip D.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (02) : 209 - 222
  • [7] In vivo divergent evolution of cross-resistance to new β-lactam/β-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment
    Cai, Heng
    Chen, Minhua
    Li, Yue
    Wang, Nanfei
    Ni, Hanming
    Zhang, Piaopiao
    Hua, Xiaoting
    Yu, Yunsong
    INFECTION, 2024, : 635 - 647
  • [8] In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
    Shields, Ryan K.
    Kline, Ellen G.
    Squires, Kevin M.
    Van Tyne, Daria
    Doi, Yohei
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (05):
  • [9] In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
    Spottiswoode, Natasha
    Hao, Samantha
    Sanchez-Guerrero, Estella
    Detweiler, Angela M.
    Mekonen, Honey
    Neff, Norma
    Macmillan, Henriette
    Schwartz, Brian S.
    Engel, Joanne
    Derisi, Joseph L.
    Miller, Steven A.
    Langelier, Charles R.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [10] Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa
    Lepper, PM
    Grusa, E
    Reichl, H
    Högel, J
    Trautmann, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) : 2920 - 2925